Evidence map›Paper›PMID 42592119›Full record

ArticleAnnals of intensive care2026

The clinical picture of ICANS after CAR-T cell therapy in critically ill patients: A retrospective clustering analysis of a multicentre multinational cohort study.

Ana Vagos-Mata, Pedro Castro, Sandrine Valade, Antoine F Carpentier, Alice Gallo de Moraes, Adel Maamar, Muriel Picard, Anne-Sophie Moreau, Sanjay Chawla, Florent Wallet and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Ana Vagos-MataDepartment of Hematology and Bone Marrow Transplant, Hospital Santa Maria, Unidade Local de Saúde Santa Maria and Faculty of Medicine, University of Lisbon, Portugal.
Pedro CastroMedical Intensive Care Unit, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain.
Sandrine ValadeCritical Care Department, APHP, Hôpital Saint-Louis, University of Paris, France.
Antoine F CarpentierParis Cité University, Assistance Publique - Hôpitaux de Paris, Neurology Department. Saint-Louis Hospital, Paris, France.
Alice Gallo de MoraesDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Adel MaamarCritical Care and Infectious Diseases Department, Rennes University Hospital, and INSERM CIC-1414, Faculté de Médecine, Université Rennes 1, France.
Muriel PicardCritical Care Department, Institut Universitaire du Cancer de Toulouse-Oncopole, University Teaching Hospital of Toulouse, France.
Anne-Sophie MoreauCritical Care Department, Salengro Hospital, CHU Lille, France.
Sanjay ChawlaCritical Care Medicine Service, Department of Anesthesiology & Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Florent WalletCritical Care Department, HCL, Hôpital Lyon Sud, University of Lyon, France.
Kada KloucheCritical Care Department, Hôpital Lapeyronie, University of Montpellier, France.
Victoria MetaxaDepartment of Critical Care, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Nicolas BoisselHematology Department, Division for Young Adults and Adolescents, Saint-Louis Hospital and Paris Cité University, France.
Andry Van De LouwDivision of Pulmonary and Critical Care Medicine, Penn State Health Milton S Hershey Medical Centre, Hershey, PA, United States.
Amélie SeguinCritical Care Department, Nantes University Hospital, France.
Djamel MokartCritical Care Department, Institut P-Calmettes, Marseille, France.
Boris BöllDepartment of Internal Medicine, Haematology and Oncology, Intensive Care Medicine, Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany.
Roberta Di BlasiParis Cité University, Assistance Publique - Hôpitaux de Paris, Hemato-oncology Department, Division for Lymphoma, Saint-Louis Hospital, Paris, France.
Catherine ThieblemontParis Cité University, Assistance Publique - Hôpitaux de Paris, Hemato-oncology Department, Division for Lymphoma, Saint-Louis Hospital, Paris, France.
Nahema IssaCritical Care Department, Hôpital Saint-André, University of Bordeaux, France.
Sara FernandezMedical Intensive Care Unit, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain.
Laveena MunshiInterdepartmental Division of Critical Care Medicine, Sinai Health System, University of Toronto, Canada.
Philippe R BauerDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Michael JoannidisDivision of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria.
Gabriel Moreno-GonzalezIntensive Care Unit, Bellvitge University Hospital, Catalan Institute of Oncology L'Hospitalet, Bellvitge Biomedical Research Institute, University of Barcelona, Spain.
Lara ZafraniCritical Care Department, APHP, Hôpital Saint-Louis, University of Paris, France.
Michael DarmonCritical Care Department, APHP, Hôpital Saint-Louis, University of Paris, France.
Elie AzoulayCritical Care Department, APHP, Hôpital Saint-Louis, University of Paris, France.
Nine-I investigators

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

CAR T-cell therapy carries significant risks, including ICANS. There is limited data on ICANS presentation and outcomes in patients admitted to ICU and it is still challenging to predict those who will have severe ICANS. This is a pre-planned substudy of an international, multicenter, observational cohort study of 241 CAR T-cell recipients for hematological malignancies, admitted to the ICU, focusing on those who developed ICANS. We aimed for a detailed description of symptoms and hierarchical clustering analysis was used to identify distinct patterns of neurological symptom presentation. ICANS was identified in 100 patients (41.5%), median age of 61 years. Most patients (93%) had non-Hodgkin lymphoma. Severe ICANS occurred in 38% of patients, associated with longer duration of symptoms (

Indexed as

CAR T-cellsHemato-oncologyICANSICUSevere ICANSSymptom clusters

Identifiers

PMID42592119
PMCPMC13464376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.